

A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina

NCT06213974

Status	RECRUITING
Sponsor	Takeda
Enrollment	10 participants

Key Eligibility Criteria

Inclusion (3)

- Adult participants (18 years or older) and pediatric participants (12 years of age and older and weighing at least 35 kilogram \[kg\]) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in the real-world setting of common clinical practice in Argentina.
- Have received at least one dose of maribavir according to approved indications.
- Have signed the mandatory informed consent/assent that has been agreed with national regulatory authorities (ANMAT) as applicable.

Locations (1 total)

IC Projects, City of Buenos Aires, Argentina